Although changes in the total amount of PPARγ may cause damage to target organs, which greatly limits its clinical application, selective activation of PPARγ provides a potential mechanism for the treatment of obesity and related diseases14, 16-18. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.